Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Diagnostic and Prognostic Serum Biomarkers for Cancer Patients Treated with Cancer Vaccines

Posted Mar 29 2011 8:00pm

Description of Invention:
Although antibodies are a critical element of the immune response, the role of antibody responses in cancer vaccines is still unknown. Carbohydrate antigens, which are directly or indirectly involved in most types of cancer vaccines, are a class of antigens has been largely understudied but play a significant role in the immune response of cancer vaccines.

This invention involves the identification of serum biomarkers for cancer that target carbohydrate antigens. The biomarkers are specific sub-populations of serum antibodies present in the serum of patients that bind to various glycan and/or glycoprotein antigens, such as the Forssman antigen.

The biomarkers are useful for a) predicting a patient’s immune responses to a cancer vaccine, b) measuring the efficacy of a cancer vaccine, and c) determining the prognosis and long-term survival of cancer patients.

Applications:
  • Diagnostic and prognostic test to monitor the progression and long-term survival of cancer patients
  • Predictive indicator of cancer patient’s immune response to a cancer vaccine
  • Indicator to monitor the efficacy of a cancer vaccine


Advantages:
The technology is backed by clinical data.

Development Status:
Preliminary clinical data; validation studies are ongoing (confirmed findings in two independent patient groups).

Inventors:
Jeff C Gildersleeve (NCI)


Patent Status:
HHS, Reference No. E-234-2010/0
US, Application No. 61/371,537 filed 06 Aug 2010
US, Application No. 61/443,955 filed 17 Feb 2011


Relevant Publication:
  1. No publications directly related to this technology.


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The Center for Cancer Research, Chemical Biology Laboratory, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize anti-glycan serum antibodies as biomarkers for cancer or HIV vaccines and/or as prognostic biomarkers. Please contact John Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Cancer
Cancer - Therapeutics
Cancer - Research Materials



For Licensing Information Please Contact:
Sabarni Chatterjee Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: chatterjeesa@mail.nih.gov
Phone: 301-435-5587
Fax: 301-402-0220


Ref No: 2246

Updated: 03/2011

Post a comment
Write a comment:

Related Searches